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Abstract
Background: Borderline ovarian tumors (BOTs) are a subset of epithelial ovarian tumors with low malignant
potential but significant risk of relapse (10% to 30%). Unfortunately, surgical prognostic factors for BOT relapse have not
been clearly identified, probably due to the use of heterogeneous surgical definitions and limited follow-up. The aim of
this study was to assess potential relapse risk factors using standard surgical definitions and long follow-up.
Methods: All patients diagnosed with BOT for a period of more than 10 years in a single institution were included in
the analysis. Complete surgical staging was defined as the set of procedures that follow standard guidelines for staging
surgery (except lymphadenectomy), performed either with one or two interventions. Fertility-sparing surgeries that
preserved one ovary and the uterus but included all the remaining procedures were classified as complete staging. The
relationship between potential risk factors and time to BOT relapse was assessed by log-rank tests corrected for
multiple comparisons and Cox regression.
Results: Forty-six patients with a median follow-up of 5.4 years were included, of whom 91.3% had been diagnosed as
FIGO stage I disease and 45.7% had received complete staging surgery. Five relapses were detected (10.9%), all of them
in women who had been diagnosed with stage I disease and had received incomplete staging surgery. Log-rank tests
confirmed the association between incomplete staging surgery and shorter time to BOT relapse.
Conclusions: Complete staging surgery should be considered a cornerstone of BOT treatment in order to minimize
the risk of relapse.
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Background
Borderline ovarian tumors (BOTs), which account for
15% of epithelial ovarian tumors, are defined by the
presence of cellular proliferation and nuclear atypia
without an infiltrative pattern or stromal invasion.
Histologically, they are divided into serous (50%), mucinous
(45%) and other subtypes (namely endometrioid, clear cell
and Brenner). The staging system of the International
Federation of Gynecology and Obstetrics (FIGO) is the
same for BOT and for invasive ovarian tumors (IOTs).
Remarkably, BOT’s extra-ovarian implants can be either
noninvasive or invasive [1,2].
Compared to IOTs, BOTs affect younger women and are
diagnosed at earlier stages, and patients have significantly
better survival rates. Approximately 85% of BOTs are
diagnosed at stage I, which confers a 98% overall survival
rate at 5 years [3]. Beyond stage II, the 5-year overall
survival is still excellent, around 85% to 92% [2,3].
However, up to 10% to 30% of patients will suffer a relapse
with locoregional (pelvic or abdominal) disease, and late
relapses are relatively common (>25% relapses occur after
5 years) [4-6]. Although most of these recurrences show
borderline histology, up to 30% of them may be IOTs,
worsening the overall survival of BOTs [7,8].
The standard of care for BOTs is complete comprehen-
sive staging surgery, defined as the exploration of the entire
abdominal cavity, bilateral oophorectomy, hysterectomy,
infracolic omentectomy, peritoneal biopsies, peritoneal
washings, removal of all macroscopic suspicious peritoneal
lesions and, for mucinous tumors, also appendectomy.
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Unfortunately, only 50% of patients undergo complete
staging. Pelvic and para-aortic lymphadenectomy do
not increase overall survival. Similarly, neither chemother-
apy nor radiotherapy are currently accepted as part of the
standard care, since randomized trials have failed to show
a benefit to survival [2]; chemotherapy is only considered
in cases of peritoneal invasive implants [9].
The low incidence of BOTs has made it difficult to
establish solid conclusions about their prognosis.
Numerous studies confirm the association of several
pathologic and clinical characteristics with an increased
risk of BOT relapse, namely older age at diagnosis [2],
invasive peritoneal implants (present in 15% to 40% of
BOTs) [10], advanced stage [2,5,8], cyst rupture [11],
stromal microinvasion [5,12-14] and elevated baseline
CA125 [8,15-18]. Invasive peritoneal implants and an
advanced stage have also been reported to decrease
overall survival [2,5,8,10,18,19]. However, the prognostic
impact of surgical procedures, such as fertility-sparing
surgery or the surgical approach (that is, laparotomy vs
laparoscopy), is currently inconclusive.
Fertility-sparing surgery (or ‘conservative’ surgery)
showed an increased risk of relapse in some studies
[2,19,20]. The general objective of this approach is the
preservation of the uterus and the contralateral, non-
affected ovary (or at least part of it) [2], but the specific
definition of the procedure (that is, including omentectomy
or not) depends on the surgical team. Moreover, secondary
complete surgery after completing childbearing is a
standard procedure in some institutions but not in
others. However, overall survival seems unaffected,
probably because a significant number of these relapses
exclusively involve the remaining ovary and can be
surgically rescued [19,20].
The findings of previous studies might also be influenced
by the length of their follow-up. A follow-up period above
5 years has been claimed to be crucial in order to properly
evaluate the relapse rate, due to the high number of late
relapses [1,6]. Indeed, relapse rates range from 5% in series
with median follow-up <3 years [21] to 30% in series with
median follow-up >5 years [5-7].
The aim of this study was to assess the potential
associations between the different surgical procedures
and the relapse rate of BOTs. With this aim, all patients
diagnosed with BOTs during an 11-year timeframe in a
single institution were classified according to strict surgical
definitions. Given the results of previous studies, we
hypothesized an association between incomplete surgical
staging and increased risk of relapse.
Methods
All patients diagnosed with BOT from 1 January 1992 to
31 December 2002 in a single institution were included
in this study. The clinical data from each participant was
collected from medical files. The variables included in
the analysis were: age, baseline CA125 and CA199 values,
type of surgical staging (complete or not), fertility-sparing
intention, surgical approach (laparoscopy or laparotomy),
performance of lymphadenectomy, histology subtype
(serous or mucinous), FIGO staging, intraoperative and
pathologic cyst rupture, presence and type of peritoneal
implants and peritoneal cytology results. Relapse and
survival information was collected after at least 5 years
of follow-up (31 December 2008).
Complete surgical staging was defined as the set of
procedures that follow standard guidelines for staging
surgery [9], independently of whether they were performed
in one or two interventions (that is, a second procedure
after completing childbearing). Fertility-sparing surgery was
defined as a procedure in which the uterus and at least
part of one ovary were preserved with the aim of pre-
serving fertility. Fertility-sparing surgery that included
all the procedures of complete surgical staging except
for hysterectomy and unilateral oophorectomy, were
considered as complete staging. Histological typing was
performed according to the World Health Organization’s
system. The staging system was based on the 2006 FIGO
stage system for ovarian cancer [1,2].
Baseline CA125 and CA199 values, type of surgery,
surgical approach, performance of lymphadenectomy,
histology subtype, FIGO staging, intraoperative and patho-
logic cyst rupture, presence of peritoneal implants and their
invasiveness and peritoneal washing cytology results were
included as potential risk factors for relapse. The time to
relapse was defined as the time from surgery to relapse.
Due to the presence of censorship (for example, because
of follow-up failure or deaths from intercurrent disease),
the influence of the potential risk factors on the time to
relapse was assessed using survival-analysis log-rank tests,
rather than simply comparing the relapse frequencies. The
false discovery rate (FDR) was used to correct for multiple
comparisons. A multivariate analysis of the risk of relapse,
as a function of the factors found to be statistically
significant prognostic factors in the univariate analysis,
was performed using Cox regression. The data were
analyzed using the SPSS (SPSS Inc, Chicago, IL) version
17.0 statistical package.
Results
Description of the sample
Forty-six women were diagnosed with BOT between
January 1992 and December 2002. The median time of
follow-up (from diagnosis to relapse or last date of
follow-up) was 5.4 years (interquartile range: 2.5 to 6
years). Their demographic characteristics are shown
in Table 1.
Twenty-five patients (54.3%) received incomplete
staging surgery. The main reason that these surgeries
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were considered ‘incomplete’ was the understaging of the
abdomen, including the lack of infracolic omentectomy,
the incomplete exploration of the entire abdominal cavity,
and the paucity of peritoneal biopsies and peritoneal
washings. There was no residual macroscopic disease in
any case. Lymphadenectomies were performed in 21 of
the 46 patients (45.7%), all of which included both pelvic
and retroperitoneal areas; the mean number of resected
nodes was 12.
Most of the patients (91.3%) were diagnosed as FIGO
stage I. Peritoneal implants were found in 3 patients
(6.7%), none of them invasive. No affected nodes were
found by the pathologic examinations of any patient.
Adjuvant treatment was not administered to any patient,
according to National Comprehensive Cancer Network
guidelines [9].
Laparotomy was the most frequent surgical approach
(87%). Intraoperative cyst rupture was observed in only
2 patients (4.5%), but the relative frequency seemed
higher in those women who had received laparoscopy
(1 out of 6 patients, 16.7%), though this difference did not
reach statistical significance (Fisher’s exact test P > 0.05).
No port site metastases were developed in patients
operated on by laparoscopy.
Three deaths were reported: two in patients free of
recurrence, and one caused by invasive tumor progression
6.7 years after the initial diagnosis (see Table 2).
The intention of surgical intervention preserving at
least one ovary and the uterus was not recorded in all of
the medical files of patients who underwent this type of
surgery. Thus, we were unable to establish whether
fertility-sparing interventions in women aged 40 to 50
who already had children should be considered as
fertility-sparing surgery or whether, conversely, they
were merely incomplete.
Recurrence characteristics
Five recurrences (10.9%) were detected (Table 2). All
patients who eventually relapsed had been considered
stage I BOT, and none of these patients had received
complete surgical staging (their interventions had been
cystectomies or unilateral adnexectomies). The mean time
for recurrence was 3.3 ± 2.1 years. Laparoscopy had been
used in 3 cases (60%). Three relapses were invasive (stage
IA mucinous IOT in the contralateral ovary, stage IIC
mucinous IOT and stage IIIC serous IOT), whilst the other
two had borderline histology (one mucinous in the
remaining ovarian tissue and the other serous in the
contralateral adnex). Thus, 3 relapses (60%) involved the
remaining adnexes exclusively, and 2 (40%) were stage II or
above. Salvage treatment at relapse was based on debulking
surgery in all patients but one, in whom a unilateral
salpingo-oophorectomy plus total abdominal hysterectomy
was performed.
At the date of last control, the three women with
relapse confined to adnexes were free of disease, the
woman with invasive stage IIIC relapse was alive with
disease and the woman with invasive stage IIC relapse
had died because of disease.
Table 1 Characteristics of the whole cohort
Number of women %
Median time of follow-up (years) 5.4
Interquartile range (years) 2.5 to 6
Mean age at diagnosis (years ± SD) 47.77 ± 16.45
Histology (n = 46):
Serous 21 45.7
Mucinous (intestinal + Müllerian) 24 52.2
Clear-cell tumor 1 2.1
CA125 or CA199 before surgery (n = 34):
Elevated (>35 UNL) 27 79.4
Normal 7 20.6
Approach (n = 46):
Laparotomy 40 87.0
Laparoscopy 6 13.0
Surgery (n = 46):
Complete 21 45.7
Incomplete 25 54.3
Lymphadenectomy (n = 46):
Pelvic +/− para-aortic 21 45.7
None 25 54.3
Intraoperative cyst rupture (n = 44):
Yes 2 4.5
No 42 95.5
Pathologic cyst rupture (n = 46):
Yes 10 21.7
No 36 78.3




Not described by surgeon 11 23.9
Peritoneal washings (n = 46):
Positive 0 0.0
Negative 46 100.0





Information not available 1 2.2
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debulking Free of disease 6.06
Neg washings CA125 = 4387
2 35.63 IC No / Yes LT Adnexectomy 2 BOT serous contralateral
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USO + TAH Free of disease 10.14
Neg washings
3 20.30 IC No / Yes LSC Cystectomy 2 BOT mucinous
intestinal
same ovary debulking Free of disease 5.80
Neg washings
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The time to relapse was found to be significantly lower
in those patients who had undergone incomplete staging
surgery (χ2 = 5. 507, degrees of freedom –df- = 1, uncor-
rected P = 0.019, FDR-corrected P = 0.038), in those
patients operated on by laparoscopy (χ2 = 8.072, df = 1,
uncorrected P = 0.004, FDR-corrected P = 0.024), and in
those patients without lymphadenectomy (χ2 = 5.862,
df = 1, uncorrected P = 0.015, FDR-corrected P = 0.038).
The omnibus test of a Cox regression using these surgical
factors was statistically significant (χ2 = 10.281, df = 3,
P = 0.016), thus rejecting the joint hypothesis that the
coefficients are all zero. Individual tests for the regression
coefficients were not statistically significant (Wald = 0.003
to 0.612, df = 1, P > 0.05), though this could potentially be
due to collinearity as these three surgical factors were not
independent (χ2 = 5.217 to 15.146, df = 1, P = 0.001 to
0.030) (Figure 1).
No significant differences were found depending on
the histology type, FIGO or the presence of pathologic
cyst rupture. The presence of intraoperative cyst ruptures,
positive peritoneal washing or peritoneal implants could
not be included in the analysis due to the low frequencies
of these events (2, 0 and 3 respectively). CA125 and
CA199 values were not included because the values were
missing in most of the patients who suffered a relapse.
There was no difference in survival between patients
who had received complete staging surgery and patients
who had not (mean survival: 9.6 vs 9.5 years, χ2 = 0.324,
df = 1, P = 0.569).
Discussion
Despite their excellent prognosis, BOTs are not a minor
health problem as 10% to 30% of patients relapse and
one third of relapses can be in form of IOTs, thus
impairing overall survival [7,8]. Moreover, BOTs affect
younger women than IOTs and often require surgery
entailing infertility. Unfortunately, surgical prognostic
factors for long-term relapse outcomes have not been
clearly established, probably due to the use of different
surgical definitions or to the short follow-up periods of
some of the reported series.
This article presents an analysis of prognostic factors
for BOT relapse in a series with a median follow-up >5
years and using the standard definition of complete
comprehensive surgical staging, even in those cases
where fertility-sparing surgery had been performed. The
proportion of patients who suffered a relapse (10.9%)
and the mean time from surgery to recurrence (3.3 ±
2.08 years) in the series presented here are similar to
those reported in other long-term follow-up series
[5,6,8,10,21-23]. The main finding was that incomplete
staging surgery significantly increased the risk of relapse.
The relapse risk was also found to be higher in patients
operated on by laparoscopy (compared to laparotomy), and
in patients who had not undergone lymphadenectomy.
Complete surgical staging has been reported to be an
important local relapse predictive factor for nearly all
tumors, and complete staging including the removal of
all macroscopic implants has been demonstrated to
improve overall survival in patients with IOTs [24,25].
However, the benefits of complete staging in patients
with BOTs could be potentially limited because: a) it might
not modify the decision regarding adjuvant treatment as
this is not the standard care; and b) most recurrences can
be salvaged. However, incomplete staging may prevent the
possibility of detecting more aggressive disease, which
could be surgically removed or be a reason to deliver
chemotherapy. In a recent series of 233 patients with BOTs
without re-staging procedures, those patients who had
undergone complete staging suffered fewer relapses than
those with incomplete staging (5.1% vs 12.3%), although
this difference was not statistically significant in the
multivariate analysis [8]. National Comprehensive Cancer
Network guidelines [9] and other authors [2] have
recommended the same complete staging procedure as is
performed on patients with IOTs. Remarkably, all patients
who suffered a relapse in our series had previously under-
gone incomplete surgical staging.
The FIGO staging classification for ovarian neoplasms is
based on surgical findings and it can only be determined
with complete surgical staging. In our sample, the percent-
age of patients with stage I disease or peritoneal implants
(91.3% and 4.3% respectively) and those receiving complete
surgical staging (45.7%) were in agreement with figures
reported in the literature [2,5,8,22,23]. Taking into account
Figure 1 Time-to-relapse analysis in patients with complete
and with incomplete staging surgery.
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the number of stage I cases among patients in this series
with incomplete surgery, a significant number of BOTs that
had been diagnosed as stage I should be better defined as
presumed stage I. This study suggests that a higher number
of complete staging procedures might result in detecting
more cases with peritoneal implants and thus, that the
incidence of stage I tumors in the literature might be
slightly overestimated. The fact that a significant number of
relapses appear in the peritoneum reinforce this idea
[3,5,8,23]. The five relapses in our sample occurred for
presumed stage I patients: the peritoneal ones were invasive
while two of the three patients who had relapses in the
remaining adnexes had borderline histology. The three
patients with adnexes-confined relapse were free of disease
in the follow-up, while the two patients who suffered an
extra-ovarian relapse were not. This is concordant with the
study of Wu et al., in which nearly all invasive relapses
occurred in the peritoneum, while most relapses with BOT
histology occurred in the adnexes [8]. We hypothesize that
complete surgical staging could minimize peritoneal and
invasive relapse.
In our series, relapse risk was also found to be signifi-
cantly higher in patients who had not undergone lympha-
denectomy. It must be noted, however, that this association
may be confounded by the fact that lymphadenectomies
were usually performed in the context of complete staging
and laparotomy, an association that might reflect the
everyday work at gynecologic services until the late 1990s,
when the number of systematic lymphadenectomies began
to decline for patients with BOTs [26]. Indeed, lymphade-
nectomy is no longer recommended for BOT treatment
because lymph node positivity has not been proved to
affect overall survival when adjusted for FIGO staging, as
reported in published retrospective series or analyses of
large databases [18,27-29].
Laparotomy was also associated with decreased risk of
relapse. However, this association could again be related
to the accrual period (1992 to 2002), as laparotomy was
the selected approach in 87% of cases. Nowadays,
surgeons have improved their laparoscopy skills and a
complete staging procedure with lower morbidity is
feasible with this approach, although the frequency of
understaging and cyst ruptures still remains high with
this technique [2,22,23]. In our series, intraoperative cyst
ruptures seemed more frequent in women operated on
by laparoscopy (16.7%) than in those operated on by
laparotomy (4.5%), like the percentages reported in 2005
by Fauvet et al. [22]. Of interest, this group found the
same relapse rate between patients who had undergone
laparotomy or laparoscopy [22].
Some limitations of this study must be highlighted.
First, its sample size was relatively small, a condition
which may have reduced the power to detect relationships
between relapse incidence and factors other than surgery,
such as FIGO staging. However, the small sample size also
implies that the relationships detected between relapse
incidence and surgical factors should probably be very
strong. Second, the low numbers in some subgroups
precluded the exploration of some of the potential prog-
nostic factors such as baseline serum markers at diagnosis,
intraoperative cyst rupture, peritoneal washings and the
presence of implants. Fortunately, the FIGO stage may
indirectly include the effects of some of these factors.
Third, the three surgical factors analyzed (type of surgery,
surgical approach and performance of lymphadenectomy)
were not independent (χ2 = 5.217 to 15.146, df = 1, P =
0.001 to 0.030), so it cannot be ruled out which one or ones
might be truly related to relapses and which might not.
However, incompleteness of surgery may probably be the
main relapse risk factor, since: a) lymphadenectomy is not
considered to be a relevant prognostic factor for BOT; b)
the relationship between laparotomy and completeness of
staging procedures could be explained by the insufficient
laparoscopic skills during the 1992 to 2002 period; and c)
all patients suffering relapses in our series were incom-
pletely staged. Finally, as mentioned earlier, this study could
not separately assess the influence of fertility-sparing
surgery in the prognosis of BOT.
Conclusions
In summary, this study, though small, stresses the
importance of complete staging of BOTs in order to
prevent peritoneal relapse, some of which may be invasive.
Moreover, complete staging enables clinicians to discover
the presence of invasive implants, which may be an indica-
tion of the need for adjuvant chemotherapy. Based on the
findings of this study, we suggest performing complete
comprehensive staging surgery in patients diagnosed
with BOT. In young patients who desire to preserve
their fertility, as well as sparing the uterus and one ovary,
we would suggest carefully exploring the abdominal cavity
and considering peritoneal abdominal staging surgery.
Further investigations are encouraged in order to better
clarify the specific roles of the different predictive factors
for relapse in long-term follow-ups (>5 years).
Abbreviations
BOT: Borderline ovarian tumor; FDR: False discovery rate; FIGO: International
Federation of Gynecology and Obstetrics; IOT: Invasive ovarian tumor.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
The authors’ contributions were as follows: MR and JR designed the study;
MR and FP retrieved the data; MR and JR conducted the statistical analyses.
All of the authors were involved in drafting the manuscript or critically
revising it and gave final approval of the version to be published. All authors
read and approved the final manuscript.
Romeo et al. World Journal of Surgical Oncology 2013, 11:13 Page 6 of 7
http://www.wjso.com/content/11/1/13
Acknowledgements
We thank Dr C. Balañá for their support and Mr F.J. Pérez for his advice on
statistics.
Author details
1Medical Oncology Department, Institut Català d’Oncologia-Badalona,
Carretera de Canyet s/n 08916, Badalona, Barcelona, Spain. 2Medical
Oncology Department, Institut Català d’Oncologia-L’Hospitalet, Gran Via de
l’Hospitalet, 199–203, l’Hospitalet de Llobregat, Barcelona 08908, Spain.
3Medical Oncology Department, Hospital del Mar-Parc de Salut Mar, Passeig
Marítim 25-29, Barcelona 08003, Spain. 4Medical Oncology Department,
Institut Català d’Oncologia-Girona, Av. França s/n. 17007, Girona, Spain.
5King’s College London, 16 De Crespigny Park, London SE5 8AF, United
Kingdom. 6FIDMAG Research Unit, CIBERSAM, C/ Dr. Antoni Pujadas, 38, Sant
Boi de Llobregat, Barcelona 08830, Spain.
Received: 11 June 2012 Accepted: 13 January 2013
Published: 23 January 2013
References
1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT,
Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 26th Annual
Report on the Results of Treatment in Gynecological Cancer. Int J
Gynaecol Obstet 2006, 95(Suppl 1):S161–S192.
2. Kadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I: Management
of borderline ovarian neoplasms. J Clin Oncol 2007, 25:2928–2937.
3. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C: Behavior of
borderline tumors with particular interest to persistence, recurrence, and
progression to invasive carcinoma: a prospective study. J Clin Oncol 2001,
19(10):2658–2664.
4. Uzan C, Kane A, Rey A, Gouy S, Pautier P, Lhomme C, Duvillard P, Morice P:
How to follow up advanced-stage borderline tumours? Mode of
diagnosis of recurrence in a large series stage II-III serous borderline
tumours of the ovary. Ann Oncol 2011, 22(3):631–635.
5. Longacre T, McKenney J, Tazelaar H, et al: Ovarian serous tumors of low
malignant potential: outcome based study of 276 patients with long
term follow up. Am J Surg Pathol 2005, 29:707–723.
6. Silva E, Gershenson D, Malpica A, et al: The recurrence and the overall
survival rates of ovarian serous borderline neoplasms with non-invasive
implants is time dependent. Americal Journal of Pathology 2006,
30(11):1367–1371.
7. Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos
C: Serous borderline tumors of the ovary with noninvasive peritoneal
implants. Cancer 1998, 83(10):2157–2163.
8. Wu TI, Lee CL, Wu MY, Hsueh S, Huang KG, Yeh CJ, Lai CH: Prognostic factors
predicting recurrence in borderline ovarian tumors. Gynecol Oncol 2009,
114(2):237–241.
9. Ovarian, fallopian tube and primary peritoneal cancers 1: NCCN clinical
practice guidelines in oncology 2013. http://www.nccn.org/professionals/
physician_gls/pdf/ovarian.pdf.
10. Morice P, Cammatte S, Rey A, Atallah D: Prognostic factors for patients
with advanced stage serous borderline tumors of the ovary. Ann Oncol
2003, 14:592–598.
11. Vergote I, De BJ, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J,
Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van GM, Trope CG: Prognostic
importance of degree of differentiation and cyst rupture in stage I invasive
epithelial ovarian carcinoma. Lancet 2001, 357(9251):176–182.
12. Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM,
Copeland L, Silva E, Gorstein F, Young RH: Borderline ovarian tumors: key
points and workshop summary. Hum Pathol 2004, 35(8):910–917.
13. McKenney JK, Balzer BL, Longacre TA: Patterns of stromal invasion in
ovarian serous tumors of low malignant potential (borderline tumors):
a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol
2006, 30(10):1209–1221.
14. Ren J, Peng Z, Yang K: A clinicopathologic multivariate analysis affecting
recurrence of borderline ovarian tumors. Gynecol Oncol 2008, 110(2):162–167.
15. Ayhan A, Seda E, Guven S, Kucukali T: Recurrence and prognostic factors
in borderline ovarian tumors. Gynecol Oncol 2005, 98:439–445.
16. Poncelet C, Fauvet R, Yazbeck C, Coutant C, Darai E: Impact of serum
tumor marker determination on the management of women with
borderline ovarian tumors: multivariate analysis of a French multicentre
study. Eur J Surg Oncol 2010, 36(11):1066–1072.
17. Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese
K, Stieber P, Burges A: Predictive value of CA 125 and CA 72–4 in ovarian
borderline tumors. Clin Chem Lab Med 2009, 47(5):537–542.
18. Camatte S, Morice P, Atallah D, Pautier P, Lhomme C, Haie-Meder C,
Duvillard P, Castaigne D: Lymph node disorders and prognostic value of
nodal involvement in patients treated for a borderline ovarian tumor: an
analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002,
195(3):332–338.
19. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Surgical management of
borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol
Oncol 2009, 113(1):75–82.
20. Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P: Outcomes after
conservative treatment of advanced-stage serous borderline tumors of
the ovary. Ann Oncol 2010, 21(1):55–60.
21. Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lécuru F: Impact of
surgical approach on the management of macroscopic early borderline
ovarian tumors. Gynecol Oncol 2005, 98:390–395.
22. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E: Laparoscopic
management of borderline ovarian tumors: results of a French
multicenter study. Ann Oncol 2005, 16(3):403–410.
23. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T: Management of
borderline ovarian tumors: results of an Italian multicenter study. Gynecol
Oncol 2006, 101(2):255–260.
24. Du BA, Quinn M, Thigpen T, Vermorken J, Vall Lundqvist E, Bookman M,
Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M,
Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener
H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar
M, Pecorelli S, Pfisterer J, Poveda A, et al: 2004 consensus statements on
the management of ovarian cancer: final document of the 3rd
International Gynecologic Cancer Intergroup Ovarian Cancer Consensus
Conference (GCIG OCCC 2004). Ann Oncol 2005, 16(Suppl 8):viii7–viii12.
25. Du BA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role
of surgical outcome as prognostic factor in advanced epithelial ovarian
cancer: a combined exploratory analysis of 3 prospectively randomized
phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire
(GINECO). Cancer 2009, 115(6):1234–1244.
26. Gershenson DM: Contemporary treatment of borderline ovarian tumors.
Cancer Invest 1999, 17(3):206–210.
27. McKenney JK, Balzer BL, Longacre TA: Lymph node involvement in ovarian
serous tumors of low malignant potential (borderline tumors):
pathology, prognosis, and proposed classification. Am J Surg Pathol 2006,
30(5):614–624.
28. Djordjevic B, Malpica A: Lymph node involvement in ovarian serous
tumors of low malignant potential: a clinicopathologic study of thirty-six
cases. Am J Surg Pathol 2010, 34(1):1–9.
29. Lesieur B, Kane A, Duvillard P, Gouy S, Pautier P, Lhomme C, Morice P, Uzan
C: Prognostic value of lymph node involvement in ovarian serous
borderline tumors. Am J Obstet Gynecol 2011, 204(5):438.e1–7.
doi:10.1186/1477-7819-11-13
Cite this article as: Romeo et al.: Incomplete staging surgery as a major
predictor of relapse of borderline ovarian tumor. World Journal of
Surgical Oncology 2013 11:13.
Romeo et al. World Journal of Surgical Oncology 2013, 11:13 Page 7 of 7
http://www.wjso.com/content/11/1/13
